What are the recommended antibiotics for Methicillin-Susceptible Staphylococcus aureus (MSSA) versus Methicillin-Resistant Staphylococcus aureus (MRSA) infections?

Antibiotic Selection for MSSA versus MRSA Infections

MSSA: First-Line Treatment

For proven MSSA infections, nafcillin, oxacillin, or cefazolin are the preferred first-line agents, with cefazolin offering superior tolerability and comparable efficacy to antistaphylococcal penicillins. 1

Parenteral Options for MSSA

• Cefazolin 1-2g IV every 8 hours is the preferred beta-lactam due to excellent efficacy and significantly better tolerability than nafcillin 1, 2
• Nafcillin or oxacillin 2g IV every 4 hours remain guideline-recommended alternatives, though associated with higher rates of premature discontinuation (33.8% vs 6.7% for cefazolin) and drug-emergent events including rash (13.9% vs 4.2%), renal dysfunction (11.4% vs 3.3%), and hepatotoxicity (8.1% vs 1.6%) 2
• Cefazolin demonstrates equivalent outcomes to oxacillin for deep-seated MSSA infections including endocarditis, with treatment failure rates of 15.6% versus 20.0% respectively 3

Important Caveat: Cefazolin Inoculum Effect

• The cefazolin inoculum effect (CzIE)—where MIC increases to ≥16 µg/mL at high bacterial loads—occurs in approximately 54% of MSSA isolates and is associated with 2.65-fold increased 30-day mortality 4
• For high-burden infections (endocarditis, osteomyelitis, large abscesses), consider nafcillin/oxacillin over cefazolin to avoid potential CzIE-related treatment failures 4

Oral Step-Down Options for MSSA

• Dicloxacillin 500mg PO four times daily is the preferred oral agent 5
• Cephalexin 500mg PO four times daily is an excellent alternative, particularly for penicillin-allergic patients without immediate hypersensitivity 1, 5
• Clindamycin 300-450mg PO three times daily for penicillin-allergic patients, if susceptible 5
• Duration: 5-10 days for uncomplicated skin/soft tissue infections; 7-14 days for complicated infections 5

Penicillin Allergy Considerations for MSSA

• First-generation cephalosporins (cefazolin, cephalexin) are safe except in immediate hypersensitivity reactions (urticaria, angioedema, bronchospasm, anaphylaxis) 6
• For severe penicillin allergy: vancomycin or clindamycin (if susceptible) 1

---

MRSA: First-Line Treatment

For proven MRSA infections, vancomycin remains the guideline-recommended first-line parenteral agent, with linezolid as an equally effective alternative particularly for pneumonia. 7

Parenteral Options for MRSA

• Vancomycin 15-20mg/kg IV every 8-12 hours (target trough 15-20 µg/mL for serious infections) is the standard of care 7
• Linezolid 600mg IV/PO twice daily demonstrates equivalent efficacy to vancomycin and is preferred for MRSA pneumonia due to superior lung penetration 7
• Daptomycin 6mg/kg IV daily for bacteremia/endocarditis (increase to 8-10mg/kg for complicated infections); contraindicated for pneumonia due to inactivation by pulmonary surfactant 7, 8
• Clindamycin 600mg IV three times daily only if susceptible and for non-endovascular infections 7

Specific MRSA Infection Types

Bacteremia/Endocarditis:

• Vancomycin 15mg/kg IV every 6-8 hours for 2-6 weeks depending on source and complications 7
• Add rifampin 300mg every 8 hours for prosthetic valve endocarditis (after bacteremia clearance) 7
• Daptomycin 6mg/kg daily is an alternative, with median time to bacteremia clearance of 8 days for MRSA 8

Pneumonia:

• Vancomycin or linezolid 600mg twice daily for 7-21 days 7
• Clindamycin 600mg three times daily if susceptible 7

Osteomyelitis:

• Minimum 8-week course with surgical debridement when feasible 7
• Options: vancomycin, daptomycin 6mg/kg daily, linezolid 600mg twice daily, or TMP-SMX 4mg/kg (TMP component) twice daily plus rifampin 600mg daily 7
• Consider adding rifampin after bacteremia clearance for biofilm penetration 7

Oral Options for MRSA

Community-acquired MRSA (non-multiresistant strains):

• Clindamycin 300-450mg PO three times daily if susceptible (check D-test for inducible resistance) 6
• TMP-SMX 1-2 double-strength tablets twice daily for skin/soft tissue infections 5
• Doxycycline 100mg PO twice daily as alternative 5
• Linezolid 600mg PO twice daily for serious infections requiring oral therapy 7

Hospital-acquired multiresistant MRSA:

• Requires combination therapy: rifampin 300-450mg twice daily PLUS fusidic acid (where available) to prevent resistance development 6
• Never use rifampin or fusidic acid as monotherapy 6

---

Critical Decision Points

When to Avoid Oral Therapy (MSSA or MRSA)

• Severe/extensive disease involving multiple sites 5
• Rapid progression with systemic illness (fever, hypotension, altered mental status) 5
• Deep-seated infections (endocarditis, osteomyelitis, septic arthritis) 5
• Immunosuppression or significant comorbidities 5
• Septic phlebitis 5

Vancomycin vs Beta-Lactams for MSSA

• Never continue vancomycin for proven MSSA when beta-lactams are available 9
• Patients switched from empiric vancomycin to nafcillin/cefazolin have 69% lower mortality hazards (HR 0.31) compared to remaining on vancomycin 9
• Vancomycin for MSSA is associated with persistent bacteremia, treatment failure, and nephrotoxicity 9

Surgical Intervention

• Mandatory for abscesses, necrotizing infections, and osteomyelitis when feasible 7, 1
• Most treatment failures occur when necessary surgical debridement is not performed 8